乐天堂fun88

Good News | Deep Harbour Cell Valley Wins the "Global Life Science Industry Park Leadership Award" at BIOHK2025

Date:09-14  Hits:  Belong to:News & Events


On September 11, 2025, at the BIOHK2025 International Biotechnology Convention held in Hong Kong, Deep Harbour Cell Valley achieved another milestone. Professor Wang Jianxun, Chief Scientist of the company, was invited to deliver a keynote speech at the main forum titled "Manufacture of CAR-T/CAR-NK cells using eVLP-based Cas9/gRNA RNP delivery system". He comprehensively shared the latest scientific research achievements and industrialization progress of Deep Harbour Cell Valley in the fields of gene editing delivery systems and key technologies for cell therapy, receiving high praise from attending experts.


During the conference, on behalf of Deep Harbour Cell Valley, Professor Wang Jianxun proudly received the "Global Life Science Industrial Park Leader Award" presented by the convention. This prestigious honor not only fully acknowledges the outstanding contributions of Deep Harbour Cell Valley in the field of cell and gene therapy (CGT) technology R&D and industrialization, but also signifies that its comprehensive strength and innovation capability have gained extensive recognition from the international industry.


Leveraging the high-end international platform of BIOHK2025, Deep Harbour Cell Valley actively engaged in global dialogues at the forefront of life sciences, showcasing to the world the innovation vitality, scientific research strength, and industrialization achievements of Chinese CGT enterprises. In the future, the company will continue to rely on Hong Kong's role as an international window, accelerate its global strategic layout, deepen cooperation with top international institutions, and jointly promote innovation and translation in cell and gene therapy technologies, bringing more new treatment options and hope for life to patients worldwide.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@wfzydp.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software